CA-GREEN-STREET
Green Street, the preeminent provider of actionable commercial real estate intelligence and analytics, has released its 2024 Pan-European Sector Outlooks, a bundle of in-depth research reports covering commercial real estate. The Outlook reports provide a 360-degree view of the four core property sectors and can be utilized in conjunction with our Market Forecasts tool, which provides five-year forecasts for operating fundamentals and valuation metrics across various scenarios for the top 30 Pan-European markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130899540/en/
New Insights! Green Street's 2024 Sector Outlooks and Expanded Market Reports Are Here. Explore Sector Dynamics, Market Fundamentals and Valuation Trends. (Graphic: Business Wire)
The 2024 Pan-European Industrial, Office, Residential and Retail Sector Outlooks include supply/demand analysis, growth forecasts, valuation metrics, and NUTS3 and Market Grades representing long-term growth potential.
“Industrial and retail remain Green Street’s preferred sectors from a long-term hold perspective. Strength of the demand has been fueling industrial rental growth, whilst high incoming yield in retail bolster returns,” explains Marie Dormeuil, Head of European Market Analytics. “On the other hand, office remains a laggard for the fourth consecutive year. The observed yield expansion is not enough to offset the drag in fundamentals entailed by the bifurcation in tenants’ demand in favour of prime offices.”
Below are key takeaways from each sector:
- Industrial: Opportunities Plentiful
M-RevPAM growth – a Green Street proprietary metric that combines effective market rent and occupancy – is forecast to exhibit a more level-playing field than history has played out, and whilst there is a wide dispersion between key European cities, growth is positive across the board. There are signals that values have bottomed and yields are showing tentative signs of tightening. Institutional investors who have been hopeful for a lower price point and/or sought greater assurance on the operating backdrop now have their potential opportunity.
- Retail: Firmer Footings
Europe's downbeat consumer has kept spending despite the uncertain outlook. The pressure on consumer discretionary spend which has been well documented in news headlines has not (yet) necessarily translated into weakening tenant sales. Retailer occupational fundamentals are surprisingly sturdy and, moreover, given the value destruction experienced in the pandemic, several green shoots are emerging in terms of rental growth. Combined with the high initial yields on offer, potential unlevered returns are alluring for centres that are dominant in their catchment. According to Green Street’s Multichannel Desirability Index, which ranks markets in order of where a retailer (and landlord) is most likely to flourish, U.K. cities screen amongst the most favourable places for both ecommerce and physical retailers.
- Office: Crystal Ball Gazing
Key risks to the office sector include a softer macro-outlook (redundancies) and improved productivity due to remote working. The bifurcation in favour of 'A' space that began to assert itself post-pandemic accelerated in '23, eroding further fundamentals for 'B'-quality. Flight to quality by tenants should accelerate operational obsolescence of some of Europe’s more secondary office stock, leading to demolition or conversion to other uses. Developers are likely to find better risk-adjusted (i.e., lower environmental impact, lower development risk) returns on offer by pursuing major refurbishment and/or redevelopment works relative to ground-up new construction projects.
- Residential: More Cheery Than Gloomy
The positive long-term structural trends of solid demand (household formation and immigration) and lack of supply outweigh the headwinds facing the European residential sector. Meanwhile, the outlook for new residential construction is muted as the rise in interest rates has derailed development economics. Pan-European residential asset prices are down ~24% from mid-'22 peak and a bottom might be forming; signals from the fixed income and public equity markets are pointing to moderate upside to private market valuations for the first time after 18 months. Governments' appetite for rent controls and stretched affordability are near-term risks to watch out for.
Request a sample report for more information on Green Street’s Sector Outlooks.
Register now to join the upcoming Pan-European Private Markets Webinar.
To learn more about Green Street’s Market Forecasts Tool, click here.
About Green Street
Green Street is the preeminent provider of actionable commercial real estate research, news, data, analytics, and advisory services in the U.S. and Europe. For more than 35 years, Green Street has delivered unparalleled intelligence and trusted data on the public and private real estate markets, helping investors, banks, lenders, and other industry participants optimize investment and strategic decisions. The firm delivers exclusive market information, conclusion-driven insights, and predictive analytics through a SaaS platform.
Green Street's US Research, Data, and Analytics products along with its global news publications are not provided as an investment advisor nor in the capacity of a fiduciary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130899540/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
